Safety and efficacy outcomes with erythropoiesisstimulating agents in patients with breast cancer: A meta-analysis

Annals of Oncology

Volumn 26, Issue 4, 2015, Pages 688-695

  Aapro, Matti ^a   Moebus, V ^b   Nitz, U ^c   O'Shaughnessy, J ^d   Pronzato, P ^e   Untch, M ^f   Tomita, D ^g   Bohac, C ^g   Leyland Jones, B ^h  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Geriatric Breast Center   (Germany)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF GENOA   (Italy)

^f HELIOS Clinic Berlin Buch   (Germany)

^g AMGEN INC   (United States)

^h Edith Sanford Breast Cancer Research   (United States)

Author keywords

Breast cancer; Chemotherapy induced anemia; Darbepoetin ; Epoetin ; Erythropoiesis stimulating agents; Meta analysis

Indexed keywords

ANTIANEMIC AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ANTINEOPLASTIC AGENT; BIOSIMILAR AGENT;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; HEART INFARCTION; HUMAN; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; THROMBOEMBOLISM; BREAST NEOPLASMS; CHEMICALLY INDUCED; COMPLICATION; DISEASE COURSE; FEMALE; PATHOLOGY; PROGNOSIS; SAFETY;

ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOSIMILAR PHARMACEUTICALS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HEMATINICS; HUMANS; PROGNOSIS; SAFETY;

EID: 84926452265     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu579     Document Type: Article

References (31)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91: 1616-1634.
2. Ludwig H, Van Belle S, Barrett-Lee P et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293-2306.
3. Houts AC, Loh GA, Fortner BV, Kallich JD. Patient and caregiver time burden associated with anaemia treatment in different patient populations. Support Care Cancer 2006; 14: 1195-1204.
4. Eder AF, Chambers LA. Noninfectious complications of blood transfusion. Arch Pathol Lab Med 2007; 131: 708-718.
5. Aapro M, Leonard RC, Barnadas A et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracyclineand/ or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol 2008; 26: 592-598.
6. Wauters I, Vansteenkiste J. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy. Expert Rev Anticancer Ther 2012; 12: 1383-1390.
7. Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299: 914-924.
8. Tonia T, Mettler A, Robert N et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012; 12: CD003407.
9. Amgen Inc. Aranesp® (Darbepoetin Alfa) Package Insert. Thousand Oaks, CA: Amgen, Inc., 2012.
10. Janssen Products LP. PROCRIT® (Epoetin Alfa) Prescribing Information. Horsham, PA: The US Food and Drug Administration 2012.
11. Glaspy J, Crawford J, Vansteenkiste J et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010; 102: 301-315.
12. Tonelli M, Hemmelgarn B, Reiman T et al. Benefits and harms of erythropoiesisstimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009; 180: E62-E71.
13. Bohlius J, Schmidlin K, Brillant C et al. Erythropoetin or darbepoetin for patients with cancer-meta-analysis based on individual patient data (Review). Cochrane Database Syst Rev 2009; CD007303.
14. Möbus V, Schneeweiss A, Du Bois A et al. Ten year follow-up analysis of intense dose-dense adjuvant ETC (epirubicin (E), paclitaxel (T) and cyclophosphamide (C)) confirms superior DFS and OS benefit in comparison to conventional dosed chemotherapy in high-risk breast cancer patients with ≥ 4 positive lymph nodes. Abstract S3-4 Cancer Res 2012; 72(24 Suppl): 97S.
15. Nitz U, Gluz O, Oberhoff C et al. Adjuvant chemotherapy with or without darbepoetin alpha in node-positive breast cancer: survival and quality of life analysis from the prospective randomized WSG ARA trial. Abstract PD07-06 Cancer Res 2011; 71(24 Suppl): 143s.
16. Nitz U, Gluz O, Zuna I et al. Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer. Ann Oncol 2014; 25: 75-80.
17. Moebus V, Jackisch C, Schneeweiss A et al. Adding epoetin alfa to intense dosedense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst 2013; 105: 1018-1026.
18. Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin-an updated overview. Nat Clin Pract Oncol 2006; 3: 152-164.
19. Chang J, Couture F, Young S et al. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005; 23: 2597-2605.
20. Del Mastro L, Venturini M, Lionetto R et al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 1997; 15: 2715-2721.
21. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23: 5960-5972.
22. Möbus V, Jackisch C, Lueck HJ et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 2010; 28: 2874-2880.
23. O'Shaughnessy JA, Vukelja SJ, Holmes FA et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 2005; 5: 439-446.
24. Pronzato P, Cortesi E, van der Rijt CC et al. Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. Oncologist 2010; 15: 935-943.
25. Untch M, von Minckwitz G, Konecny GE et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicincyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer-outcome on prognosis. Ann Oncol 2011; 22: 1999-2006.
26. O'Shaughnessy JA. Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer 2002; 3(Suppl 3): S116-S120.
27. Nitz U, Oberhoff C, Reimer T et al. Adjuvant chemotherapy with or without darbepoetin in node-positive breast cancer: a safety analysis from the phase III ARA plus trial. Cancer Res 2009; 69(2 suppl): Abstr 4100.
28. Untch M, Fasching PA, Konecny GE et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel +/- darbepoetin alfa in primary breast cancer-results at the time of surgery. Ann Oncol 2011; 22: 1988-1998.
29. Chavez-MacGregor M, Zhao H, Fang S et al. Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study. Cancer 2011; 117: 3641-3649.
30. Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008; 13(Suppl 3): 33-36.
31. Swain S, Tang G, Geyer C et al. NSABP B-38: definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC→paclitaxel (P) plus gemcitabine (G) with DD AC→P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. J Clin Oncol 2002; 30: Abstr LBA1000.